Institution
Zambian Ministry of Health
Government•Lusaka, Zambia•
About: Zambian Ministry of Health is a government organization based out in Lusaka, Zambia. It is known for research contribution in the topics: Population & Malaria. The organization has 391 authors who have published 617 publications receiving 17719 citations.
Topics: Population, Malaria, Tuberculosis, Health care, Public health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, the authors report on the feasibility and early outcomes of the program, which scaled-up human immunodeficiency virus/acquired immunoviciency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka using predominately nonphysician clinicians.
Abstract: ContextThe Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians.ObjectiveTo report on the feasibility and early outcomes of the program.Design, Setting, and PatientsOpen cohort evaluation of antiretroviral-naive adults treated at 18 primary care facilities between April 26, 2004, and November 5, 2005. Data were entered in real time into an electronic patient tracking system.InterventionThose meeting criteria for antiretroviral therapy (ART) received drugs according to Zambian national guidelines.Main Outcome MeasuresSurvival, regimen failure rates, and CD4 cell response.ResultsWe enrolled 21 755 adults into HIV care, and 16 198 (75%) started ART. Among those starting ART, 9864 (61%) were women. Of 15 866 patients with documented World Health Organization (WHO) staging, 11 573 (73%) were stage III or IV, and the mean (SD) entry CD4 cell count among the 15 336 patients with a baseline result was 143/μL (123/μL). Of 1142 patients receiving ART who died, 1120 had a reliable date of death. Of these patients, 792 (71%) died within 90 days of starting therapy (early mortality rate: 26 per 100 patient-years), and 328 (29%) died after 90 days (post-90-day mortality rate: 5.0 per 100 patient-years). In multivariable analysis, mortality was strongly associated with CD4 cell count between 50/μL and 199/μL (adjusted hazard ratio [AHR], 1.4; 95% confidence interval [CI], 1.0-2.0), CD4 cell count less than 50/μL (AHR, 2.2; 95% CI, 1.5-3.1), WHO stage III disease (AHR, 1.8; 95% CI, 1.3-2.4), WHO stage IV disease (AHR, 2.9; 95% CI, 2.0-4.3), low body mass index (<16; AHR,2.4; 95% CI, 1.8-3.2), severe anemia (<8.0 g/dL; AHR, 3.1; 95% CI, 2.3-4.0), and poor adherence to therapy (AHR, 2.9; 95% CI, 2.2-3.9). Of 11 714 patients at risk, 861 failed therapy by clinical criteria (rate, 13 per 100 patient-years). The mean (SD) CD4 cell count increase was 175/μL (174/μL) in 1361 of 1519 patients (90%) receiving treatment long enough to have a 12-month repeat.ConclusionMassive scale-up of HIV and AIDS treatment services with good clinical outcomes is feasible in primary care settings in sub-Saharan Africa. Most mortality occurs early, suggesting that earlier diagnosis and treatment may improve outcomes.
695 citations
••
TL;DR: Pyrimethamine-sulphadoxine (PSD) is usually deployed as a successor to chloroquine, but resistance to PSD is increasing and a health calamity looms within the next few years.
531 citations
••
University of London1, Zambian Ministry of Health2, University College London3, Centers for Disease Control and Prevention4, Children's Hospital at Westmead5, Liverpool School of Tropical Medicine6, College of Health Sciences, Bahrain7, Health Protection Agency8, Ludwig Maximilian University of Munich9, Alfaisal University10, National Institutes of Health11, Karolinska Institutet12
TL;DR: The development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined, and a rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed.
Abstract: Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010. This assay was specifically recommended for use as the initial diagnostic test for suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of countries with a high tuberculosis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated the assay into their national tuberculosis programme guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review the rapidly growing body of scientific literature and discuss the advantages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics pipeline should remain a major priority for funders and researchers.
415 citations
••
Kenyatta University1, Liverpool School of Tropical Medicine2, University of London3, University of Tübingen4, Karolinska Institutet5, Lusaka Apex Medical University6, Zambian Ministry of Health7, Muhimbili University of Health and Allied Sciences8, National Institute for Medical Research9, Indian Institute of Technology Delhi10, Stellenbosch University11, University of Cape Coast12, University of Maryland, Baltimore13, Johns Hopkins University14, University of Cape Town15, University of Pittsburgh16, Queen Mary University of London17, Barts Health NHS Trust18, University College London19
TL;DR: In 2019, TB remained the most common cause of death from a single infectious pathogen globally, and an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV as discussed by the authors.
371 citations
••
TL;DR: Care provided by clinicians such as nurses and clinical officers can result in good outcomes for HIV-infected children in primary health care settings in sub-Saharan Africa, suggesting a need for earlier intervention.
Abstract: the 1561 children who had at least 1 repeat measurement was 12.9% (95% CI, 12.5%13.3%) and increased to 23.7% (95% CI, 23.1%-24.3%) at 6 months, 27.0% (95% CI, 26.3%-27.6%) at 12 months, 28.0% (95% CI, 27.2%-28.8%) at 18 months, and 28.4% (95% CI, 27.4%-29.4%) at 24 months.
361 citations
Authors
Showing all 398 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert L. Goldenberg | 111 | 712 | 48398 |
Tran Tinh Hien | 96 | 302 | 39329 |
Sten H. Vermund | 69 | 606 | 22181 |
Peter Mwaba | 48 | 132 | 7386 |
Moses Joloba | 48 | 284 | 8106 |
Jeffrey S. A. Stringer | 47 | 241 | 8202 |
Matthew Bates | 40 | 130 | 5268 |
Nathan Kapata | 30 | 88 | 2947 |
Busiku Hamainza | 28 | 82 | 2284 |
Moses Sinkala | 27 | 55 | 3271 |
Namwinga Chintu | 25 | 45 | 2300 |
John M. Miller | 25 | 68 | 1757 |
Elwyn Chomba | 24 | 75 | 2211 |
Mwaka Monze | 22 | 52 | 1598 |
Godfrey Biemba | 21 | 65 | 1362 |